Anjali Sharma, MD

Anjali is a Pediatric Hematologist-Oncologist who trained at Lucile Packard Children’s Hospital, Stanford. During her fellowship, she also did a fellowship in Adult Bone Marrow and Stem Cell transplant at Stanford Medical center.She completed her medical degree at Lady Hardinge Medical School in New Delhi, India and finished her Pediatric residency at UIC, Chicago.

After completion of fellowship she worked at UCSF at their Pediatric Bone Marrow and Stem Cell transplant division. Subsequently she joined Kaiser Permanente and worked as an attending physician in the division of Pediatric Hematology- Oncology covering the SF bay area.

In 2015, she joined Amgen and was the US medical lead ( medical affairs) for Aranesp and Nplate. She joined the clinical development team as a Clinical Research Medical director in 2017 and in 2019, became an Early Development lead, leading 2 teams in early Hematology- Oncology.

In 2021, Anjali joined CRISPR therapeutics and was the Global Development lead for the Thalassemia trial of CTX 001( Exa-cel) gene therapy. She then switched back to Oncology as the Global Development lead for CTX 130 which is a CD70 directed allogeneic CAR-T therapy. More recently she has joined Gilead Sciences where she is the Pediatric Oncology global development lead.